Medical/Pharmaceuticals

Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions

SHANGHAI, April 22, 2024 /PRNewswire/ -- Themed "Planet vs. Plastics," the 55th Earth Day serves as a deep reminder for everyone to play a role in environmental protection.Angel Yeast , (SH600298), the world's leading yeast and biotechnology company, is actively promot...

2024-04-22 16:00 2454

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

SUZHOU, China, April 21, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced thatthe China phase II clinical trial (the "Phase II Clinical Trial") of i...

2024-04-22 09:53 1401

Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards

SINGAPORE, April 18, 2024 /PRNewswire/ -- Juniper Biologics

2024-04-22 09:00 949

Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate LiveWire Global Awards

SINGAPORE, April 22, 2024 /PRNewswire/ -- Juniper Biologics

2024-04-22 09:00 1045

BGI Genomics Leads Innovation with Inaugural Clinical Lab in Uruguay

Cutting-edge facility to serve as a beacon for preventive medicine in Latin America MONTEVIDEO, Uruguay, April 22, 2024 /PRNewswire/ -- BGI Genomics, a global leader in integrated precision medicine solutions, has established a new clinical laboratory atUruguay's Parque de las Ciencias free trad...

2024-04-22 08:27 1034

CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US

TAMPA, Fla., April 20, 2024 /PRNewswire/ -- Concept Medical , a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" usingMagicTouch

2024-04-20 01:11 1742

Inaugural 'Korea Medical Innovation Research Forum' regular seminar, a success

* To be registered as an official research organization by the National Assembly Secretariat... Expected to become Korea's leading medical think tank * Planning to initiate global multinational clinical projects in digital therapeutics * Establishing a future medical system centered aroun...

2024-04-19 21:00 2308

Concord Medical Files 2023 Annual Report on Form 20-F

BEIJING, April 19, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it filed its annual report on Form 20-F for t...

2024-04-19 20:31 2347

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

GAITHERSBURG, Md., April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2024-04-19 19:00 3464

GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer

SHANGHAI, April 19, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a mult...

2024-04-19 19:00 1767

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

SEOUL, South Korea, April 19, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com ) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue vi...

2024-04-19 13:17 1502

Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

SEOUL, South Korea, April 18, 2024 /PRNewswire/ -- South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi,www.hyundaibioscience.com ) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue...

2024-04-19 10:54 1827

Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions

Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 /PRNewswire/ -- Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a...

2024-04-18 21:00 1844

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

GAITHERSBURG, Md., April 18, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2024-04-18 20:00 1184

European Wellness Leads Pioneering Down Syndrome Research at Heidelberg University

HEIDELBERG, Germany, April 18, 2024 /PRNewswire/ -- The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomi...

2024-04-18 16:17 1176

Siriraj Hospital Shines Spotlight on TAVI Procedure as Alternative for High-Risk Patients Requiring Aortic Valve Replacement

BANGKOK, April 18, 2024 /PRNewswire/ -- Siriraj Hospital, a leading healthcare institution inThailand, stands at the forefront of aortic valve disease treatment with Transcatheter Aortic Valve Implantation (TAVI). The minimally invasive procedure significantly reduces surgical trauma and post-sur...

2024-04-18 15:01 1438

TaiGen Successfully Completes TG-1000 Phase III Study

TAIPEI, April 17, 2024 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to alleviation of al...

2024-04-18 11:03 1157

Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build "Australia's next CSL"

MELBOURNE, Australia, April 18, 2024 /PRNewswire/ -- Australia's newest biotech incubatorJumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaitedMelbourne-based facility at an ...

2024-04-18 11:00 1536

Datasea Secures Combined $15 Million with its Second Sales Contract for Acoustic Products

BEIJING, April 17, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence ("AI") multimodal communication technology inthe United State...

2024-04-17 22:00 1045

Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity

SHANGHAI, April 17, 2024 /PRNewswire/ -- On April 17, 2024, Henlius (2696.HK) released its 2023 Environmental, Social and Governance (ESG) report (hereinafter referred to as "ESG report" or "report"). The report comprehensively discloses the Company's initiatives and achievements in promoting is...

2024-04-17 20:32 1282
12345 ... 576